ALFA FinderBSE filing, NSE: SANDUPHQ. Summary written from the filing by ALFA Finder's alert engine.
Sandu Pharmaceuticals Ltd: key numbers
- Share price
- ₹36.72
- Market cap
- ₹35.48 Cr
- Revenue (annual)
- ₹69.93 Cr
- Net profit (annual)
- ₹1.77 Cr
- P/E (TTM)
- 14.6×Sector 43.0×
- Promoter holding
- 37.79%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sandu Pharmaceuticals Ltd
All →Sandu Pharmaceuticals Board Meeting Date
Sandu Pharmaceuticals scheduled a board meeting on November 14, 2026, to approve unaudited financial results. The meeting covers the quarter and half-year ended September 30, 2026.
Sandu Pharmaceuticals Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals intimated that Non-Executive Independent Director Dr Neeti Madan Kapre has changed her name to Dr Neeti Gupta after marriage. The DIN, designation and directorship remain unchanged.
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals Limited has issued a reminder to physical shareholders regarding the mandatory submission of PAN and KYC details. This compliance follow-up aims to facilitate electronic dividend payments.
Sandu Pharmaceuticals Management Change
Sandu Pharmaceuticals appointed Dr. Neeti Madan Kapre as director and Dave & Dave as statutory auditor, while announcing other board and auditor tenure changes.
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals has appointed M/s. Dave & Dave as Statutory Auditors for a five-year term, following the tenure expiry of the previous auditors.
Other annual report announcements
All →Generic Engineering Construction and Projects Annual Report
Generic Engineering filed its FY2025-26 Annual Report ahead of its 32nd AGM on 30 November 2026. The filing covers board changes and a planned bank-funded EPC expansion.
Vineet Laboratories Annual Report
Vineet Laboratories filed its FY 2025-26 Annual Report, which marks its turnaround and recapitalisation year. The AGM is scheduled for 30 November 2026.
Indrayani Biotech Annual Report
Indrayani Biotech has filed its 34th Annual Report for FY2025-26, containing the AGM notice for 30 November 2026 by VC/OAVM. The chairman notes a Rights Issue was initiated in October 2026 to raise capital.
ESDS Software Solution Annual Report
ESDS Software Solution submitted its FY2025-26 Annual Report along with the AGM notice. The AGM is on 30 November 2026 via VC/OAVM, with remote e-voting.
The Orissa Minerals Development Company Annual Report
Orissa Minerals Development Company filed its FY 2025-26 Annual Report and 108th AGM notice, with the AGM set for 30 November 2026. The filing is a Regulation 34 intimation with no transaction or financial event.
Viksit Engineering Annual Report
Viksit Engineering filed its 44th Annual Report for FY 2025-26 with BSE. The report includes notice of the AGM on 30 November 2026.